Pulmatrix Inc (PULM)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

99 HAYDEN AVENUE LEXINGTON, MA 02421

Ruthigen, Inc. is a biopharmaceutical company. The company discovers, develops, manufactures and retails pharmaceutical-grade hypochlorous acid based therapeutics designed to prevent and treat infection in invasive applications. Ruthigen offers its products to the medical and healthcare industries.

Data as of 2020-11-22
Market Cap37.504 Million Shares Outstanding34.407 Million Avg 30-day Volume425.734 Thousand
P/E Ratio-1.5 Dividend Yield EPS-0.75
Price/Sales3.044 Price cash flow ratio3.4 Price free cash flow ratio-2.6
Book Value0.68 Price to Tangible Book1.88 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.025877
BETA1.66427 52-week High/Low2.055 / 0.76 Stddev0.43598
View SEC Filings from PULM instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 1 0.0% 0 (0.0%) 0 (0.0%)
Funds Holding: 25 27 -7.41% 9 (0.59%) 7 (0.45%) 28.57%
13F shares: 7.429 Million 5.254 Million 41.39% 4.965 Million 2.521 Million 96.98%
% Ownership 21.5912 20.5179 5.23% 14.4305 9.843 46.61%
New Positions: 6 10 -40.0% 2 2 0.0%
Increased Positions 11 6 83.33% 4 1 300.0%
Closed Positions 7 2 250.0% 1
Reduced Positions 1 2 -50.0% 2
Total Calls 0 0
Total Puts 0 0
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding PULM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PULM BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BAZEMORE TODD

  • Director
0 2020-10-01 2

GILLIS STEVEN

  • Director
0 2020-08-28 3

CABELL CHRISTOPHER

  • Director
0 2020-06-23 2

HIGGINS MICHAEL J

  • Director
0 2020-04-21 3

IWICKI MARK T

  • Director
0 2020-04-02 2

RAAD TEOFILO DAVID CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-04-02 2

MUNSHI AMIT

  • Director
0 2020-04-02 2

BATYCKY RICHARD P.

  • Director
0 2020-04-02 2

SIEGERT MICHELLE VICE PRESIDENT OF FINANCE

  • Officer
0 2020-01-09 1

MCGUIRE TERRANCE

  • Director
0 2019-05-16 0

DUKE WILLIAM E. CHIEF FINANCIAL OFFICER

  • Officer
0 2019-05-16 0

SHERMAN MATTHEW L

  • Director
0 2019-05-16 0

CLARKE ROBERT W. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2018-06-05 0

HAVA DAVID L. CHIEF SCIENTIFIC OFFICER

  • Officer
0 2018-06-05 0

ROACH JAMES M. CHIEF MEDICAL OFFICER

  • Officer
0 2018-06-05 0

MCGUIRE TERRANCE

FLINT JONATHAN A

POLARIS VENTURE MANAGEMENT CO IV LLC

POLARIS VENTURE PARTNERS ENTREPRENEURS FUND IV LP

POLARIS VENTURE PARTNERS IV LP

POLARIS VENTURE MANAGEMENT CO. V, L.L.C.

POLARIS VENTURE PARTNERS ENTREPRENEURS' FUND V, L.P.

POLARIS VENTURE PARTNERS V, L.P.

POLARIS VENTURE PARTNERS FOUNDERS' FUND V, L.P.

POLARIS VENTURE PARTNERS SPECIAL FOUNDERS' FUND V, L.P.

  • Director
  • 10% Owner
5,180,235 2018-04-03 0

GILLIS STEVEN

ARCH VENTURE FUND VII LP

ARCH VENTURE PARTNERS VII, L.P.

ARCH VENTURE PARTNERS VII, LLC

CRANDELL KEITH

BYBEE CLINTON

NELSEN ROBERT

  • Director
  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
3,436,456 2018-04-03 0

ARCH VENTURE FUND VII LP

ARCH VENTURE PARTNERS VII, L.P.

ARCH VENTURE PARTNERS VII, LLC

CRANDELL KEITH

BYBEE CLINTON

NELSEN ROBERT

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
No longer subject to file 2018-04-03 0

GRAVES KURT

  • Director
0 2016-02-03 0

ROCKLAGE SCOTT M

  • Director
0 2016-02-03 0

OCULUS INNOVATIVE SCIENCES, INC.

  • 10% Owner
0 2015-06-16 0

MAKI DAVID

  • Director
436,388 2015-06-15 0

CONLEY RICHARD K

  • Director
0 2015-04-30 0

FRENCH GREGORY M

  • Director
0 2015-04-30 0

AKAO AKIHISA

  • Director
0 2015-04-30 0

HARISH SAMEER CHIEF FINANCIAL OFFICER

  • Officer
74,600 2014-05-11 0

ALIMI HOJABR CEO AND CHIEF SCIENCE OFFICER

  • Officer
  • Director
125,000 2014-05-11 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

HIGGINS MICHAEL J - Director

2016-02-25 12:54:48 -0500 2026-02-03 A 8,800 a 8,800 direct

BAZEMORE TODD - Director

2020-10-02 16:15:40 -0400 2020-10-01 A 30,000 a 30,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments